In our lung cancer quiz, you’ll get to test your knowledge on the BFAST study.
What is BFAST (NCT03178552)?
a. A study investigating whether upfront brain radiotherapy is superior to “at progression” brain radiotherapy in patients with non-small cell lung cancer (NSCLC) and asymptomatic brain metastases.
b. An ongoing global study evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations in circulating tumor DNA and activity of targeted therapies and immunotherapy in patients with first-line advanced NSCLC.
c. A study which assessed the effect of molecular testing and the introduction of novel therapeutic options on the use of systemic therapy and overall survival for patients with advanced NSCLC.
d. A study which evaluated the efficacy and safety of AB928 plus carboplatin, pemetrexed, and a PD-1 antibody in patients with metastatic NSCLC.